Soon H. Lee

FAM is a growth manager that uses proprietary, bottom-up, fundamental research to identify companies that are undergoing positive dynamic change. The firm invests in companies experiencing high unit volume growth and/or companies undergoing a positive life cycle change.

Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations.

FrontPoint Partners employs a variety of hedging strategies including absolute return, multi-strategy, quantitative equity arbitrage, distressed securities, global fixed-income relative value, convertible arbitrage, long/short equity, market neutral, global emerging markets, and quantitative macro. They use fundamental analysis with a bottom-up stock selection approach. In general, the firm invests in the stocks of US companies in the technology services, utilities, industrial services healthcare technology, energy minerals and finance sectors. They invest across all market-caps, with emphasis on the stocks of large-cap companies. FrontPoint Partners maintains a very high turnover rate

Operates as a biotechnology company that develops neurology therapies

Functions as a College/University

Provides strategic advisory and principal investment services

Functions as a College/University